Anavex Life Sciences Corp (AVXL)

[polarbear77]

Not sure if you were seeking feedback but i found it a bit disingenuous for you to cast doubt and uncertainty on Anavex for adjusting dosages when this was a ph2/2a adaptive trial PURPOSELY designed with SAFETY and Maximum Tolerated Dose as the PRIMARY endpoints, and SECONDARY endpoints of EXPLORATORY cognition and function.

But, of course, you were already aware of that.

And I might add that insinuating that Dr M is “uncomfortable” with 2-73 by twisting one line (out of context) from his recent interview is somewhat low-brow IMO.

To each his own I suppose.

Quick aside, slides 26-27 from the Sept 2017 pk/pd Ariana presentation illustrated to the scientific community that a majority of our >4 ng/mL blood concentration Alzheimer’s Disease participants IMPROVED/STABILIZED over 57 weeks (4 improved, 1 stable out of 9 total).

http://www.anavex.com/my_uploads/ANAVEX2-73-PKPD-Phase-2a-2017.pdf

That’s what you see too, right? It’s a pretty simple to follow chart.

And approximately 20 times during their presentation Ariana indicated that they’d found a strong/clear dose dependent relationship and/or blood concentration level correlation with cognitive test scores.

That is a positive too correct? A sensical correlation with dose/blood concentration and cognitive response (per the data analytics experts at Ariana).

Does that provide you any sense of joy (as an analytical person)?

Ariana is telling us that (once that blood level concentration was achieved) a majority of our trial participants that reached said level (9 in total) were IMPROVED (4) and STABLE (1) through 57 weeks. That’s my understanding.

On behalf of CNS disease sufferers and their families, that’s encouraging and worthy of furtherance into the next confirmatory trial, am I right?

I’m assuming that you’re for this type of progress rather than against it. Although I’m confused by some of your posts.

Are you interested in supporting a company that is reporting dose dependent (blood concentration level dependent) improvement in Alzheimer’s Disease patients?

[You’ve already previously told me that we’ve no reason to question the reputation/work product of the well respected data analytics experts from Ariana.]

I won’t bore you with the markedly increased safety profile of 2-73 as compared to the nasty side effects of the current SOC drugs for AD; since you’re already aware of that as well.

Enjoy your weekend


[All should DYODD, I’m long and have that bias; anything is still possible, manage your own risks]